This post was originally published on this site Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation titled, “Overall survival (OS) results of the phase III…
This post was originally published on this site Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in the brain and reduced the amount of senile plaques in a mouse model of Alzheimer’s disease. The study with that finding, “Long-Term Dabigatran Treatment Delays Alzheimer’s Disease Pathogenesis…
This post was originally published on this site Fujifilm SonoSite is collaborating with the Allen Institute of Artificial Intelligence (AI2) Incubator to use artificial intelligence to improve the accuracy of ultrasound images, the standard way to detect ovarian cancer. A developer of bedside and point-of-care ultrasound, Fujifilm SonoSite paired with the AI2 Incubator to use…
This post was originally published on this site IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials show. The data, confirming that both trials achieved their primary endpoints, were presented at the 22nd Annual…
This post was originally published on this site Phio Pharmaceuticals and researchers with Helmholtz Zentrum München — the German Research Center for Environmental Health (HMGU) — are working together to develop new approaches to boost the immune system in fighting cancer. The collaboration aims to use Phio’s proprietary self-delivering RNAi (sd-rxRNA) technology to inhibit checkpoint molecules in…
This post was originally published on this site A new injectable flutamide formulation called Liproca Depot is safe, well-tolerated and shows sustained efficacy in untreated men with localized prostate cancer, according to early results of a Phase 2b clinical trial. The LPC-004 Phase 2b trial (NCT03348527) is ongoing at specialist urology clinics in Canada, Lithuania, and…
This post was originally published on this site Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP) Registry, allowing people with multiple myeloma to securely submit their health data to MMRF CureCloud, the foundation’s data repository. This is the first data repository to gather people’s longitudinal…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Ofev (nintedanib) for the treatment of patients with sarcoidosis and other types of progressive fibrosing interstitial lung diseases (ILDs). The breakthrough designation is given to medications that provide significant advantages over currently available…
This post was originally published on this site Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy alone, a Phase 3 trial shows. The research, “Clinical Outcomes by Chemotherapy Regimen in Patients with RS…
This post was originally published on this site Anavex Life Sciences has launched an extension study — called ATTENTION-AD — to investigate the long-term safety and efficacy of Anavex 2-73 in delaying cognitive decline in people with early Alzheimer’s disease. Eligible patients are those now taking part in the company’s 48-week ANAVEX2-73-AD-004 study underway in…
